Figure 1.
Distribution of patients per final titrated dose for patients starting ruxolitinib at 15 mg twice daily (bis in die [BID]) (A) versus 20 mg BID (B).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.